Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Sarawgi

What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Bristol-Myers Squibb Company (BMY) is one of the leading biopharmaceutical companies focused on developing treatments for cancer, inflammatory, immunologic, cardiovascular and fibrotic diseases. With a market cap of $119.8 billion, Bristol-Myers’ operations span various countries in the Americas, Europe, and the Indo-Pacific.

The Princeton, New Jersey-based pharma giant has slightly lagged behind the S&P 500 over the past year. BMY has gained 19.7% over the past 52 weeks, compared to the S&P 500 Index’s ($SPX) 23.3% surge during the same time frame. However, BMY has soared 4.6% on a YTD basis outpacing SPX’s 2.6% gains in 2025.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.